Beyond Minoxidil: Off-Label Therapies for Male Androgenetic Alopecia-A Systematic Review with Network Meta-Analyses.
Topical minoxidil 5% is considered the most effective off-label therapy for male androgenetic alopecia, but other treatments may also show potential benefits.
Where it sits
this study against the rest of the abs-201 corpusSummary and findings
This study evaluated the comparative effectiveness of off-label therapies for male androgenetic alopecia (AGA) through a network meta-analysis. It included a systematic review of 23 studies, focusing on the mean 6-month change in total hair density. Topical minoxidil 5% was found to be the most effective treatment among those assessed.
Abstract
<i>Background</i>: There is limited evidence on comparative effectiveness of off-label therapies approved by the United States Food and Drug Administration (FDA) for androgenetic alopecia (AGA) and the unregulated ones. <i>Objective</i>: To evaluate and compare the molecular mechanisms, clinical efficacy, and safety of off-label therapies for male AGA through a network meta-analysis (NMA). <i>Methods</i>: A systematic literature search in PubMed, Scopus, Web of Science, and ClinicalTrials.gov was conducted on 23 January 2026. We examined studies that assessed mean 6-month change in total hair density of off-label monotherapies, including topical minoxidil (2%, 5%) for male AGA. Sensitivity analyses were conducted. <i>Results</i>: Our search identified 23 studies (15 off-label and 8 topical minoxidil). We found topical minoxidil 5% to be ranked most effective. Other effective therapies included melatonin (topical), diaminopyrimidine oxide 1% (topical), procyanidin 1% (topical), saw palmetto (topical), exosome-based formulation containing plant-derived extracts (subcutaneous), cetirizine 1% (topical) and finasteride (topical). <i>Conclusions</i>: Our results substantiate topical minoxidil 5% being the most effective option; our findings also suggest that other off-label therapies demonstrate potential clinical benefit, warranting further high-quality comparative trials.
Background
This paper addresses the comparative effectiveness of off-label therapies for male androgenetic alopecia (AGA), a condition with limited treatment options. Previous studies have primarily focused on FDA-approved treatments, with little systematic comparison of off-label alternatives. Understanding the efficacy and safety of these therapies is crucial for clinicians considering treatment options for AGA.
Methods
The study utilized a systematic literature search across multiple databases, including PubMed and Scopus, conducted on 23 January 2026. It included studies that assessed the mean 6-month change in total hair density for off-label monotherapies, specifically topical minoxidil at doses of 2% and 5%. The analysis involved 23 studies, with sensitivity analyses performed to validate findings.
Results
Topical minoxidil 5% was identified as the most effective therapy for male AGA among the treatments evaluated. The study included 23 studies, comprising 15 off-label therapies and 8 studies on topical minoxidil. Specific numeric outcomes for hair density changes were not provided in the abstract.
Interpretation
The findings suggest that while topical minoxidil 5% is the most effective treatment, other off-label therapies may also offer clinical benefits. However, the lack of detailed numeric outcomes limits the ability to assess the clinical significance of these findings. Additionally, the reliance on existing studies introduces variability in quality and methodology, which may confound the results.
Key findings
- Topical minoxidil 5% ranked most effective among therapies evaluated.
- 23 studies included in the analysis: 15 off-label and 8 topical minoxidil.
- Other effective therapies included melatonin (topical), diaminopyrimidine oxide 1% (topical), procyanidin 1% (topical), saw palmetto (topical), exosome-based formulation containing plant-derived extracts (subcutaneous), cetirizine 1% (topical), and finasteride (topical).
- Mean 6-month change in total hair density was the primary outcome measure.
- Sensitivity analyses were conducted.
Limitations
- Not all therapies evaluated provided specific numeric outcomes.
- The study relies on existing literature, which may vary in quality.
- No direct comparisons of effect sizes among therapies were reported.
- Sensitivity analyses do not guarantee the robustness of findings.